Biological therapies are an effective treatment for a range of immune-mediated inflammatory
diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Background Biosimilars have been used for 15 years in the European Union (EU), and have
been shown to reduce costs and increase access to important biological medicines. In spite …

Compared with the original approved biological drug on which it is based, a biosimilar has
highly similar physicochemical characteristics and biological activity, as well as equivalent …

Over time, clinicians have become increasingly comfortable embracing the prescription of
biosimilars—highly similar versions of innovator or reference biological agents—for their …

Aims Adalimumab is a biological therapy used to treat different chronic inflammatory
diseases. At present, there is an increasing number of adalimumab biosimilars. To assume …

Abstract Background Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab
biosimilar with similar efficacy and comparable safety and immunogenicity to reference …

Background As the economic burden of treating cancer patients has been soaring in
European countries, performing a budget impact analysis is becoming one of the …

Background Pharmacists being the drug experts need to be well aware of the applied
handling of biosimilar medicines (BSMs). They are an integral educator, trailblazer, and …

Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-
modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that …